TY - JOUR
T1 - PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence
T2 - real-world experience from the Unicancer network
AU - Rippstein, Nicolas
AU - Zemmour, Christophe
AU - Rodrigues, Manuel
AU - Ray-Coquard, Isabelle
AU - Gladieff, Laurence
AU - Pautier, Patricia
AU - Frénel, Jean Sébastien
AU - Costaz, Hélène
AU - Lebreton, Coriolan
AU - Pomel, Christophe
AU - Colombo, Pierre Emmanuel
AU - Marchal, Frédéric
AU - Guillemet, Cécile
AU - de la Motte Rouge, Thibault
AU - Eberst, Lauriane
AU - Bosquet, Lise
AU - Deluche, Elise
AU - Sabatier, Renaud
N1 - Publisher Copyright:
© The Author(s) 2025. Published by Oxford University Press.
PY - 2025/5/1
Y1 - 2025/5/1
N2 - Background: Based on results of randomized clinical trials, polyADP‐ribose polymerase inhibitors (PARPi) have become the standard of care in patients with platinum-sensitive recurrent ovarian cancer (OvC) in patients responding to platinum chemotherapy. However, little is known about their impact on survival in a real-world setting. Patients and methods: This retrospective French multicenter observational study included women with platinum-sensitive recurrent OvC (not limited to the first platinum-sensitive relapse) receiving PARPi as maintenance after response to platinum-based chemotherapy. They were compared to patients with similar characteristics undergoing observation after chemotherapy completion. Data were collected in the Ovarian Cancer Epidemiological Strategy and Medical Economics (ESME-OC) database between 2011 and 2021. We explored progression-free survival (PFS) and overall survival (OS) benefits with PARPi maintenance. Results: One hundred and twenty-three patients matching the selection criteria were included in the PARPi group and 397 patients in the control group. Median PFS was 19.9 months (95CI [15.0-21.9]) in the PARPi group vs 13.4 months (95CI [11.8-15.0]) in the control group, with a HR = 0.71 (95CI [0.55-0.93]), P = .01). Median OS was 82.0 months (95CI [48.6-Not Estimable]) in the PARPi group vs 44.7 months (95CI [38.8-53.7]) in the control group (HR = 0.47, 95CI [0.30-0.74], P < .001). Multivariate analyses including performance status, histological subtype, achievement of cytoreductive surgery at relapse, and platinum-free interval, confirmed the independent prognostic impact of PARPi treatment. Conclusion: This first national study focusing on the efficacy of PARPi in a real-world population shows similar benefits than in randomized clinical trials, supporting their use in clinical routine practice. Database registration: clinicaltrials.gov Identifier NCT03275298.
AB - Background: Based on results of randomized clinical trials, polyADP‐ribose polymerase inhibitors (PARPi) have become the standard of care in patients with platinum-sensitive recurrent ovarian cancer (OvC) in patients responding to platinum chemotherapy. However, little is known about their impact on survival in a real-world setting. Patients and methods: This retrospective French multicenter observational study included women with platinum-sensitive recurrent OvC (not limited to the first platinum-sensitive relapse) receiving PARPi as maintenance after response to platinum-based chemotherapy. They were compared to patients with similar characteristics undergoing observation after chemotherapy completion. Data were collected in the Ovarian Cancer Epidemiological Strategy and Medical Economics (ESME-OC) database between 2011 and 2021. We explored progression-free survival (PFS) and overall survival (OS) benefits with PARPi maintenance. Results: One hundred and twenty-three patients matching the selection criteria were included in the PARPi group and 397 patients in the control group. Median PFS was 19.9 months (95CI [15.0-21.9]) in the PARPi group vs 13.4 months (95CI [11.8-15.0]) in the control group, with a HR = 0.71 (95CI [0.55-0.93]), P = .01). Median OS was 82.0 months (95CI [48.6-Not Estimable]) in the PARPi group vs 44.7 months (95CI [38.8-53.7]) in the control group (HR = 0.47, 95CI [0.30-0.74], P < .001). Multivariate analyses including performance status, histological subtype, achievement of cytoreductive surgery at relapse, and platinum-free interval, confirmed the independent prognostic impact of PARPi treatment. Conclusion: This first national study focusing on the efficacy of PARPi in a real-world population shows similar benefits than in randomized clinical trials, supporting their use in clinical routine practice. Database registration: clinicaltrials.gov Identifier NCT03275298.
KW - : real word data
KW - PARP inhibitor
KW - maintenance therapy
KW - platinum-sensitive
KW - recurrent ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=105004819228&partnerID=8YFLogxK
U2 - 10.1093/oncolo/oyaf075
DO - 10.1093/oncolo/oyaf075
M3 - Article
AN - SCOPUS:105004819228
SN - 1083-7159
VL - 30
JO - Oncologist
JF - Oncologist
IS - 5
M1 - oyaf075
ER -